By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Singulex, Inc. 

1701 Harbor Bay Parkway

Alameda  California  94502  U.S.A.
Phone: 510-814-9000 Fax: 510-814-9018


About Singulex, Inc.

Singulex is the developer and leading provider of Single Molecule Counting (SMC™) technology for clinical diagnostics and scientific discovery. Singulex’s proprietary SMC technology enables physicians and scientists to detect biomarkers of disease that were previously undetectable. Powered by SMC technology, Singulex’s ultrasensitive immunoassay solutions and lab testing services are transforming patient care from reactive disease treatment to proactive health management and fueling the discovery and development of new therapeutics. Singulex provides SMC technology to leading pharmaceutical R&D laboratories, clinical research organizations (CROs) and academic institutions around the world through its Research-Use-Only Erenna® Immunoassay System. The Singulex Clinical Lab Testing Services consist of a CLIA-licensed and CAP-accredited laboratory that currently provides a comprehensive menu of advanced cardiovascular disease testing utilizing SMC technology. Singulex is developing the Singulex Clinical Diagnostic System, a fully-automated in vitro diagnostics system that will bring the benefits of its SMC technology to hospital and reference labs worldwide. For further information, please visit

About Singulex’s Erenna Platform

Powered by Single Molecule Counting (SMC™) technology, Singulex’s Research-Use-Only Erenna® Immunoassay System’s ability to measure small changes in biomarkers such as cardiac troponin I and cytokines, and to monitor these changes over time, has expanded the clinical utility of established markers. The Erenna system helps power the discovery and development of innovative lab developed tests and treatments for chronic diseases such as cardiovascular disease, Alzheimer’s disease, oncology, rheumatoid arthritis and diabetes.

Key Statistics

Ownership: Private

Web Site: Singulex, Inc.


Company News
U.S. Patent Awarded To Singulex, Inc. For Expanded Use Of Biomarkers Troponin I And T To Detect Cardiac Health Status With Single-Molecule Methods 11/12/2015 7:16:20 AM
Singulex, Inc. Receives European Patent Expanding Use Of Biomarkers Troponin I And T To Detect Cardiac Health Status With High-Sensitivity Methods 11/5/2015 9:56:15 AM
Singulex, Inc. Demonstrates Ultrasensitive "Sgx Clarity System"At AACC 2015 7/14/2015 1:20:06 PM
Singulex, Inc. Announces EMD Group (EMD Millipore Headquarters) To Acquire Exclusive Rights To Singulex's Ultra-Sensitive Single Molecule Counting (SMC) Technology 5/21/2015 2:08:37 PM
Singulex, Inc. Announces Partnership With The Dutch Technology Foundation (STW) To Accelerate The Development Of Clinical Biomarkers 4/30/2015 1:19:38 PM
Singulex, Inc. Key Patent Granted In Japan For Detecting Or Monitoring Cardiovascular Disease Using Proprietary Biomarkers 4/28/2015 10:51:50 AM
Singulex, Inc. Announces Collaboration With CHDI Foundation To Develop Biomarker Assays For Huntington's Disease 4/9/2015 9:12:18 AM
Singulex, Inc. Announces Expansion Of National Sales Force For Clinical Lab Business 10/21/2014 10:30:59 AM
Presentation Of Ten Abstracts Using Singulex, Inc.'s SMC(TM) Technology And Preview Of Sgx Clarity™ System Are Featured At European Society of Cardiology Congress 2014 9/5/2014 8:11:58 AM
Singulex, Inc. Announces Preview Of The Sgx Clarity™ IVD System And Presentation Of 10 Abstracts Demonstrating Single Molecule (SMC™) Technology Performance In Cardiovascular Disease At 2014 European Society of Cardiology Congress 8/27/2014 7:52:38 AM